Objectives-To investigate the prevalence
and characteristics of antibodies to endothelial cells (aEC) from large vessel and from microvasculature in a group of patients with Behcet's disease (BD) to determine the relationship of these antibodies with clinical and laboratory features of the disease. Methods-Thirty patients with BD were prospectively and consecutively studied. The aEC were determined by enzymelinked immunosorbent assay (ELISA) using endothelial cells derived from human umbilical vein (large vessel) as well as from retroperitoneal adipose tissue (microvasculature). Results-Fifteen patients (50%) had aEC, either directed to large vessel [8(26%) patients] or microvascular [13(43%) patients] endothelial cells. The percenitage of active patients was significantly higher in the aEC-positive group [12(80%) patients] compared with the aEC-negative group [5(33%) However, four patients (13%) had a history of past thrombotic events (deep vein thrombosis in two cases and superior vena cava thrombosis in the remaining two cases). Conventional tests for detection of lupus anticoagulant, as well as for anticardiolipin, antineutrophil cytoplasmic, antinuclear, anti-DNA, anti-Ro(SSA), antiLa(SSB), anti-RNP, and anti-Sm antibodies, were negative in all patients.
There was no significant difference between aEC-positive and -negative patients in age and sex distribution. However, the percentage of active patients was significantly higher in the aEC-positive group compared with the aECnegative group (p < 0 05). Specifically, 12 (80%) of 15 aEC-positive patients, but five (33%) of the remaining 15 aEC-negative patients, had active disease. Furthermore, the prevalence of active eye lesions and central nervous system involvement at the time of the assay were higher in aEC-positive patients (53% and 20%, respectively) compared with the prevalence in aEC-negative patients (20% and 0%), although these differences did not reach statistical significance. All four patients with a history of past thrombotic events had both aEC derived from human umbilical vein and aEC from human adipose tissue. There were no differences in the other clinical and serological features between aEC-positive and -negative patients.
Discussion
In this study, we have demonstrated that patients with BD have a high prevalence of aEC when microvascular endothelial cells are used in the assay. Pivetti-Pezzi et al9 have previously investigated the prevalence of aEC from human umbilical vein, as well as that of anticardiolipin antibodies, in a cohort of Italian patients with BD characterised by a high degree of genetic homogeneity and by the presence of retinal vasculitis. While an elevated prevalence of anticardiolipin antibodies was found, aEC were identified only in a minority of patients (23%). In another study, Aydintug et al'0 disclosed a statistically significant higher prevalence of aEC in a group of 72 Turkish patients with BD (18% v 0% in health controls). These aEC were not cytotoxic for the endothelial monolayers in vitro, but their presence correlated with an active disease and with acute thrombotic events. In contrast, anticardiolipin antibodies were negative in all Turkish patients. The discrepancy between these two reports can be related to the different disease activity or to the diverse genetic background of the patients included.
Our finding of a higher prevalence of aEC when endothelial cells derived from microvasculature were used in the ELISA is of special relevance. 
